Validation of the PsAID - GOPAID

  • Research type

    Research Study

  • Full title

    Investigation and Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire

  • IRAS ID

    180784

  • Contact name

    Neil McHugh

  • Contact email

    neil.mchugh@nhs.net

  • Sponsor organisation

    Royal United Hospitals Bath NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 10 months, 1 days

  • Research summary

    Psoriatic Arthritis (PsA) is a chronic inflammatory arthritis affecting up to 40% of people with skin and nail psoriasis (Wilson et al 2009). Disease activity and joint damage contribute to reduced physical and psychosocial health-related
    quality of life, with significant social and economic impact (Boehncke et al 2013). Psoriasis is a complex disease, and has many clinical manifestations including involvement of the joints, tendons (the sinew joining muscle to bone) as well as the spine. A number of tools have been developed to measure disease activity, but these tools use physical examination and blood tests to calculate a score. The European League Against Rheumatism (EULAR) recognized the need to develop a way of measuring the impact of PsA on individual patients, to develop a patient-centered score. In 2014 a tool called the Psoriatic Arthritis Impact of Disease Questionnaire (or PsAID for short) was designed, and has been tested in a study population (Gossec et al 2014).
    This study will test the reliability and usability of the PsAID in hospital outpatients. Two groups will be studied – those patients with stable disease, and those patients requiring an increase in medication to control their arthritis. The PsAID will be recorded and compared to other questionnaires and disease activity scores already in use to see how it performs and what extra information it provides. The questionnaires should be able to be completed in 30 minutes. It is hoped that the PsAID will prove to be a useful tool for assessing the impact of PsA from the patient’s perspective, and help guide treatment decisions.

  • REC name

    Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

  • REC reference

    15/YH/0250

  • Date of REC Opinion

    27 May 2015

  • REC opinion

    Favourable Opinion